T Cell Subsets are Associated with Clinical Activity and Efficacy of 4.5g Intravenous Glucocorticoid for Moderate-To-Severe Thyroid-Associated Ophthalmopathy

References

• Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, et al. Therapy with different dose regimens of rituximab in patients with active moderate-to-severe graves’ orbitopathy. Front Endocrinol (Lausanne). 2022;12:790246. doi:10.3389/fendo.2021.790246.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168–199. doi:10.1210/edrv.21.2.0393.
   PubMed Web of Science ®Google Scholar
• Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14(6):747–793. doi:10.1210/edrv-14-6-747.
   PubMed Web of Science ®Google Scholar
• Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353–360. doi:10.2169/internalmedicine.53.1518.
   PubMed Web of Science ®Google Scholar
• Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26(3):273–279. doi:10.1016/j.beem.2011.10.005.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med. 2009;360(10):994–1001. doi:10.1056/NEJMcp0806317.
   PubMed Web of Science ®Google Scholar
• Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1735–1748. doi:10.1167/iovs.14-14002.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedüs LG. Disease. N Engl J Med. 2016;375(16):1552–1565. doi:10.1056/NEJMra1510030.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134–142. doi:10.1016/s2213-8587(16)30046-8.
   PubMed Web of Science ®Google Scholar
• Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves’ disease. Nat Rev Dis Primers. 2020;6(1):52. doi:10.1038/s41572-020-0184-y.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Invest. 2010;33(6):414–421. doi:10.1007/bf03346614.
   PubMed Web of Science ®Google Scholar
• Karoutsou E, Polymeris A. Pathogenesis of Graves’ disease focusing on Graves’ ophthalmopathy. Endocr Regul. 2011;45(4):209–220. doi:10.4149/endo_2011_04_209.
   PubMedGoogle Scholar
• Salvi M. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):409–414. doi:10.1097/med.0000000000000097.
   PubMedGoogle Scholar
• Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142–150. doi:10.1136/bjophthalmol-2015-307399.
   PubMed Web of Science ®Google Scholar
• Li H, Wang T. The autoimmunity in Graves’s disease. Front Biosci (Landmark Ed). 2013;18(2):782–787. doi:10.2741/4141.
   PubMedGoogle Scholar
• Gianoukakis AG. Smith TJ.Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2008;15(5):446–452. doi:10.1097/MED.0b013e32830eb8ab.
   PubMedGoogle Scholar
• Pawlowski P, Reszec J, Eckstein A, Johnson K, Grzybowski A, Chyczewski L, et al. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical implications. Mediators Inflamm. 2014;412158. doi:10.1155/2014/412158.
   PubMed Web of Science ®Google Scholar
• Virakul S, van Steensel L, Dalm VA, Paridaens D, van Hagen PM, Dik WA. Platelet-derived growth factor: a key factor in the pathogenesis of graves’ ophthalmopathy and potential target for treatment. Eur Thyroid J. 2014;3(4):217–226. doi:10.1159/000367968.
   PubMedGoogle Scholar
• Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: cD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009;50(5):2262–2268. doi:10.1167/iovs.08-2328.
   PubMed Web of Science ®Google Scholar
• Hai YP, Lee ACH, Frommer L, Diana T, Kahaly GJ. Immunohistochemical analysis of human orbital tissue in Graves’ orbitopathy. J Endocrinol Invest. 2020;43(2):123–137. doi:10.1007/s40618-019-01116-4.
   PubMed Web of Science ®Google Scholar
• Grubeck-Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, Wick G. Retrobulbar T cells from patients with Graves’ ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest. 1994;93(6):2738–2743. doi:10.1172/JCI117289.
   PubMed Web of Science ®Google Scholar
• Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, et al. Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy. JAMA Ophthalmol. 2018;136(6):613–619. doi:10.1001/jamaophthalmol.2018.0806.
   PubMed Web of Science ®Google Scholar
• Vaidya B, Shenton BK, Stamp S, Miller M, Baister E, Andrews CD, et al. Analysis of peripheral blood T-cell subsets in active thyroid-associated ophthalmopathy: absence of effect of octreotide-LAR on T-cell subsets in patients with thyroid-associated ophthalmopathy. Thyroid. 2005;15(9):1073–1078. doi:10.1089/thy.2005.15.1073.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. doi:10.1056/NEJMoa1614949.
   PubMed Web of Science ®Google Scholar
• Genere N, Stan MN. Current and emerging treatment strategies for Graves’ Orbitopathy. Drugs. 2019;79(2):109–124. doi:10.1007/s40265-018-1045-9.
   PubMed Web of Science ®Google Scholar
• Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104–116. doi:10.1038/s41574-019-0305-4.
   PubMed Web of Science ®Google Scholar
• Bartley GB. Gorman CA.Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol. 1995;119(6):792–795. doi:10.1016/s0002-9394(14)72787-4.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273–285. doi:10.1530/eje-07-0666.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang S, Zhang Y, Liu X, Gu H, Zhong S, et al. A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy. BMC Endocr Disord. 2018;18(1):13. doi:10.1186/s12902-018-0240-8.
   PubMedGoogle Scholar
• Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–332. doi:10.1210/jc.2010-1962.
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14. doi:10.1046/j.1365-2265.1997.2331047.x.
   PubMed Web of Science ®Google Scholar
• Naselli A, Moretti D, Regalbuto C, Arpi ML, Lo Giudice F, Frasca F, et al. Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves’ ophthalmopathy to parenteral corticosteroids. Front Endocrinol (Lausanne). 2020;11:609895. doi:10.3389/fendo.2020.609895.
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. doi:10.1002/1097-0142(1950)3:1<32:AID-CNCR2820030106>3.0.CO;2-3.
   PubMed Web of Science ®Google Scholar
• Khoo TK, Bahn RS. Pathogenesis of Graves’ ophthalmopathy: the role of autoantibodies. Thyroid. 2007;17(10):1013–1018. doi:10.1089/thy.2007.0185.
   PubMed Web of Science ®Google Scholar
• Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 2000;52(3):267–271. doi:10.1046/j.1365-2265.2000.00959.x.
   PubMed Web of Science ®Google Scholar
• Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab. 2010;95(5):2123–2131. doi:10.1210/jc.2009-2470.
   PubMed Web of Science ®Google Scholar
• Tyutyunikov A, Raikow RB, Kennerdell JS, Kazim M, Dalbow MH, Scalise D. Re-examination of peripheral blood T cell subsets in dysthyroid orbitopathy. Invest Ophthalmol Vis Sci. 1992;33(7):2299–2303. PMID: 1351477.
   PubMed Web of Science ®Google Scholar
• Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol. 2015;11(3):171–181. doi:10.1038/nrendo.2014.226.
   PubMed Web of Science ®Google Scholar
• Otto EA, Ochs K, Hansen C, Wall JR, Kahaly GJ. Orbital tissue-derived T lymphocytes from patients with Graves’ ophthalmopathy recognize autologous orbital antigens. J Clin Endocrinol Metab. 1996;81(8):3045–3050. doi:10.1210/jcem.81.8.8768872.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94(5):1803–1809. doi:10.1210/jc.2008-2450.
   PubMed Web of Science ®Google Scholar
• Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2000;85(2):776–780. doi:10.1210/jcem.85.2.6333.
   PubMed Web of Science ®Google Scholar
• Hu H, Liang L, Ge Q, Jiang X, Fu Z, Liu C, et al. Correlation between peripheral t cell subsets and the activity of thyroid-associated ophthalmopathy. Int J Endocrinol. 2022;2022:2705650. doi:10.1155/2022/2705650.
   PubMed Web of Science ®Google Scholar
• Chen W, Ford MS, Young KJ, Zhang L. The role and mechanisms of double negative regulatory T cells in the suppression of immune responses. Cell Mol Immunol. 2004;1(5):328–335. PMID: 16285891.
   PubMed Web of Science ®Google Scholar
• Xu D, Wu Y, Gao C, Qin Y, Zhao X, Liang Z, et al. Characteristics of and reference ranges for peripheral blood lymphocytes and CD4+ T cell subsets in healthy adults in Shanxi province, North China. J Int Med Res. 2020;48(7):1–13. doi:10.1177/0300060520913149.
   Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association/European group on Graves’ Orbitopathy guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9–26. doi:10.1159/000443828.
   PubMed Web of Science ®Google Scholar
• Zhu W, Ye L, Shen L, Jiao Q, Huang F, Han R, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves’ ophthalmopathy. J Clin Endocrinol Metab. 2014;99(6):1999–2007. doi:10.1210/jc.2013-3919.
   PubMed Web of Science ®Google Scholar
• Jeong S, Lemke BN, Dortzbach RK, Park YG, Kang HK. The Asian upper eyelid: an anatomical study with comparison to the Caucasian eyelid. Arch Ophthalmol. 1999;117(7):907–912. doi:10.1001/archopht.117.7.907.
   PubMedGoogle Scholar
• Huang Y, Fang S, Li D, Zhou H, Li B. Fan X.The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond). 2019;33(2):176–182. doi:10.1038/s41433-018-0279-9.
   PubMed Web of Science ®Google Scholar
• Pappa A, Lawson JM, Calder V, Fells P, Lightman S. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol. 2000;84(5):517–522. doi:10.1136/bjo.84.5.517.
   PubMed Web of Science ®Google Scholar
• Fang S, Huang Y, Wang N, Zhang S, Zhong S, Li Y, et al. Insights into local orbital immunity: Evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2019;104(5):1697–1711. doi:10.1210/jc.2018-01626.
   PubMed Web of Science ®Google Scholar
• Cari L, De Rosa F, Nocentini G, Riccardi C. Context-dependent effect of glucocorticoids on the proliferation, differentiation, and apoptosis of regulatory t cells: A review of the empirical evidence and clinical applications. Int J Mol Sci. 2019;20(5). doi:10.3390/ijms20051142.
   Web of Science ®Google Scholar
• Strehl C, Ehlers L, Gaber T. Buttgereit F.Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. doi:10.3389/fimmu.2019.01744.
   PubMed Web of Science ®Google Scholar
• Xing L, Ye L, Zhu W, Shen L, Huang F, Jiao Q, et al. Smoking was associated with poor response to intravenous steroids therapy in Graves’ ophthalmopathy. Br J Ophthalmol. 2015;99(12):1686–1691. doi:10.1136/bjophthalmol-2014-306463.
   PubMed Web of Science ®Google Scholar